Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival

Natale Cascinelli, Emilio Bombardieri, Rosaria Bufalino, Tiziana Camerini, Antonino Carbone, Claudio Clemente, Leonardo Lenisa, Luigi Mascheroni, Andrea Maurichi, Elisabetta Pennacchioli, Roberto Patuzzo, Mario Santinami, Gabrina Tragni

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the prognostic significance of sentinel node biopsy in the management of stage IB and II melanoma patients, and to evaluate the status of nonsentinel nodes as a "second step key factor" to assess the prognosis of these patients. Patients and Methods: We conducted an analysis of data collected in a prospective database. Results: From February 1994 to June 2005, 1, 108 consecutive patients with stage IB and II melanoma were submitted to sentinel node biopsy; 176 patients (15.9%) had occult node metastases. The frequency of positive nodes increased with increasing Breslow's thickness. The largest diameter of metastatic foci and their localization within the lymph node were associated with the risk of nonsentinel node metastases only. The 5-year survival of patients with positive sentinel nodes was 81.4% in patients with one positive node and 39.6% in patients with two positive nodes (P = .056). Multivariate analysis indicated that status of sentinel nodes is a key factor and that sex and Breslow's thickness maintain statistically significant relevance. Ulceration, which was associated with survival when considered as single factor ( P<.001) had no impact on survival in the multivariate analysis (P = .10). To evaluate the relevance of metastases to nonsentinel nodes, we identified four groups of patients. Conclusion: Evaluation of the sentinel node is a useful procedure to identify patients to be submitted for complete lymph node dissection. The procedure makes it possible to assess the best prognosis of patients.

Original languageEnglish
Pages (from-to)4464-4471
Number of pages8
JournalJournal of Clinical Oncology
Volume24
Issue number27
DOIs
Publication statusPublished - Sep 20 2006

Fingerprint

Melanoma
Survival
Neoplasm Metastasis
cyhalothrin
Multivariate Analysis
Biopsy
Sex Factors
Lymph Node Excision
Lymph Nodes
Databases

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cascinelli, N., Bombardieri, E., Bufalino, R., Camerini, T., Carbone, A., Clemente, C., ... Tragni, G. (2006). Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. Journal of Clinical Oncology, 24(27), 4464-4471. https://doi.org/10.1200/JCO.2006.06.3198

Sentinel and nonsentinel node status in stage IB and II melanoma patients : two-step prognostic indicators of survival. / Cascinelli, Natale; Bombardieri, Emilio; Bufalino, Rosaria; Camerini, Tiziana; Carbone, Antonino; Clemente, Claudio; Lenisa, Leonardo; Mascheroni, Luigi; Maurichi, Andrea; Pennacchioli, Elisabetta; Patuzzo, Roberto; Santinami, Mario; Tragni, Gabrina.

In: Journal of Clinical Oncology, Vol. 24, No. 27, 20.09.2006, p. 4464-4471.

Research output: Contribution to journalArticle

Cascinelli, N, Bombardieri, E, Bufalino, R, Camerini, T, Carbone, A, Clemente, C, Lenisa, L, Mascheroni, L, Maurichi, A, Pennacchioli, E, Patuzzo, R, Santinami, M & Tragni, G 2006, 'Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival', Journal of Clinical Oncology, vol. 24, no. 27, pp. 4464-4471. https://doi.org/10.1200/JCO.2006.06.3198
Cascinelli, Natale ; Bombardieri, Emilio ; Bufalino, Rosaria ; Camerini, Tiziana ; Carbone, Antonino ; Clemente, Claudio ; Lenisa, Leonardo ; Mascheroni, Luigi ; Maurichi, Andrea ; Pennacchioli, Elisabetta ; Patuzzo, Roberto ; Santinami, Mario ; Tragni, Gabrina. / Sentinel and nonsentinel node status in stage IB and II melanoma patients : two-step prognostic indicators of survival. In: Journal of Clinical Oncology. 2006 ; Vol. 24, No. 27. pp. 4464-4471.
@article{732a08b9c5b14db9a3346fd5204cddba,
title = "Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival",
abstract = "Purpose: To evaluate the prognostic significance of sentinel node biopsy in the management of stage IB and II melanoma patients, and to evaluate the status of nonsentinel nodes as a {"}second step key factor{"} to assess the prognosis of these patients. Patients and Methods: We conducted an analysis of data collected in a prospective database. Results: From February 1994 to June 2005, 1, 108 consecutive patients with stage IB and II melanoma were submitted to sentinel node biopsy; 176 patients (15.9{\%}) had occult node metastases. The frequency of positive nodes increased with increasing Breslow's thickness. The largest diameter of metastatic foci and their localization within the lymph node were associated with the risk of nonsentinel node metastases only. The 5-year survival of patients with positive sentinel nodes was 81.4{\%} in patients with one positive node and 39.6{\%} in patients with two positive nodes (P = .056). Multivariate analysis indicated that status of sentinel nodes is a key factor and that sex and Breslow's thickness maintain statistically significant relevance. Ulceration, which was associated with survival when considered as single factor ( P<.001) had no impact on survival in the multivariate analysis (P = .10). To evaluate the relevance of metastases to nonsentinel nodes, we identified four groups of patients. Conclusion: Evaluation of the sentinel node is a useful procedure to identify patients to be submitted for complete lymph node dissection. The procedure makes it possible to assess the best prognosis of patients.",
author = "Natale Cascinelli and Emilio Bombardieri and Rosaria Bufalino and Tiziana Camerini and Antonino Carbone and Claudio Clemente and Leonardo Lenisa and Luigi Mascheroni and Andrea Maurichi and Elisabetta Pennacchioli and Roberto Patuzzo and Mario Santinami and Gabrina Tragni",
year = "2006",
month = "9",
day = "20",
doi = "10.1200/JCO.2006.06.3198",
language = "English",
volume = "24",
pages = "4464--4471",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "27",

}

TY - JOUR

T1 - Sentinel and nonsentinel node status in stage IB and II melanoma patients

T2 - two-step prognostic indicators of survival

AU - Cascinelli, Natale

AU - Bombardieri, Emilio

AU - Bufalino, Rosaria

AU - Camerini, Tiziana

AU - Carbone, Antonino

AU - Clemente, Claudio

AU - Lenisa, Leonardo

AU - Mascheroni, Luigi

AU - Maurichi, Andrea

AU - Pennacchioli, Elisabetta

AU - Patuzzo, Roberto

AU - Santinami, Mario

AU - Tragni, Gabrina

PY - 2006/9/20

Y1 - 2006/9/20

N2 - Purpose: To evaluate the prognostic significance of sentinel node biopsy in the management of stage IB and II melanoma patients, and to evaluate the status of nonsentinel nodes as a "second step key factor" to assess the prognosis of these patients. Patients and Methods: We conducted an analysis of data collected in a prospective database. Results: From February 1994 to June 2005, 1, 108 consecutive patients with stage IB and II melanoma were submitted to sentinel node biopsy; 176 patients (15.9%) had occult node metastases. The frequency of positive nodes increased with increasing Breslow's thickness. The largest diameter of metastatic foci and their localization within the lymph node were associated with the risk of nonsentinel node metastases only. The 5-year survival of patients with positive sentinel nodes was 81.4% in patients with one positive node and 39.6% in patients with two positive nodes (P = .056). Multivariate analysis indicated that status of sentinel nodes is a key factor and that sex and Breslow's thickness maintain statistically significant relevance. Ulceration, which was associated with survival when considered as single factor ( P<.001) had no impact on survival in the multivariate analysis (P = .10). To evaluate the relevance of metastases to nonsentinel nodes, we identified four groups of patients. Conclusion: Evaluation of the sentinel node is a useful procedure to identify patients to be submitted for complete lymph node dissection. The procedure makes it possible to assess the best prognosis of patients.

AB - Purpose: To evaluate the prognostic significance of sentinel node biopsy in the management of stage IB and II melanoma patients, and to evaluate the status of nonsentinel nodes as a "second step key factor" to assess the prognosis of these patients. Patients and Methods: We conducted an analysis of data collected in a prospective database. Results: From February 1994 to June 2005, 1, 108 consecutive patients with stage IB and II melanoma were submitted to sentinel node biopsy; 176 patients (15.9%) had occult node metastases. The frequency of positive nodes increased with increasing Breslow's thickness. The largest diameter of metastatic foci and their localization within the lymph node were associated with the risk of nonsentinel node metastases only. The 5-year survival of patients with positive sentinel nodes was 81.4% in patients with one positive node and 39.6% in patients with two positive nodes (P = .056). Multivariate analysis indicated that status of sentinel nodes is a key factor and that sex and Breslow's thickness maintain statistically significant relevance. Ulceration, which was associated with survival when considered as single factor ( P<.001) had no impact on survival in the multivariate analysis (P = .10). To evaluate the relevance of metastases to nonsentinel nodes, we identified four groups of patients. Conclusion: Evaluation of the sentinel node is a useful procedure to identify patients to be submitted for complete lymph node dissection. The procedure makes it possible to assess the best prognosis of patients.

UR - http://www.scopus.com/inward/record.url?scp=33749054227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749054227&partnerID=8YFLogxK

U2 - 10.1200/JCO.2006.06.3198

DO - 10.1200/JCO.2006.06.3198

M3 - Article

C2 - 16983115

AN - SCOPUS:33749054227

VL - 24

SP - 4464

EP - 4471

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 27

ER -